Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Bibliographic Details
Main Authors:	Fabio Guolo, Claudio Cerchione, Chiara Vernarecci, Alessandro Isidori
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Oncology
Subjects:	acute myeloid leukemia (AML) minimal residual disease (MRD) immunotherapy allogeneic stem cell transplantation leukemic stem cell (LSC)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1020185/full

Similar Items

MRD Tailored Therapy in AML: What We Have Learned So Far
by: Lok Lam Ngai, et al.
Published: (2021-01-01)

Location First: Targeting Acute Myeloid Leukemia Within Its Niche
by: Alice Pievani, et al.
Published: (2020-05-01)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
by: Cumbo C, et al.
Published: (2020-05-01)

Characterization of CD34<sup>+</sup> Cells from Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Using a t-Distributed Stochastic Neighbor Embedding (t-SNE) Protocol
by: Cathrin Nollmann, et al.
Published: (2024-03-01)

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
by: Tali Azenkot, et al.
Published: (2022-07-01)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
by: Riana van der Linde, et al.
Published: (2023-10-01)

Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect
by: H. Moses Murdock, et al.
Published: (2024-03-01)

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
by: Justin Loke, et al.
Published: (2021-05-01)

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
by: Ilias Pessach, et al.
Published: (2022-09-01)

Understanding the Hedgehog Signaling Pathway in Acute Myeloid Leukemia Stem Cells: A Necessary Step toward a Cure
by: Daniel Lainez-González, et al.
Published: (2021-03-01)

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia
by: Laurène Pousse, et al.
Published: (2023-05-01)

Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells
by: Lindsey A. Murphy, et al.
Published: (2023-12-01)

Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study
by: Teresa Caballero-Velázquez, et al.
Published: (2023-03-01)

Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia
by: Azza M. Kamel, et al.
Published: (2022-04-01)

LSD1 inhibition modulates transcription factor networks in myeloid malignancies
by: Emily E. Hartung, et al.
Published: (2023-03-01)

Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in China
by: Jie Ding, et al.
Published: (2024-12-01)

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection
by: Kritika Srinivasan Rajsri, et al.
Published: (2023-05-01)

The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia
by: Andrew Wu, et al.
Published: (2023-03-01)

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
by: Nikhil Patkar, et al.
Published: (2019-06-01)

Treatment options for acute myeloid leukemia patients aged <60 years
by: Giuseppe Visani, et al.
Published: (2022-10-01)

Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review
by: Alexandra Teixeira, et al.
Published: (2023-02-01)

The Potential Role of 3D In Vitro Acute Myeloid Leukemia Culture Models in Understanding Drug Resistance in Leukemia Stem Cells
by: Basil Al-Kaabneh, et al.
Published: (2022-10-01)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)

Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
by: Toshiki Terao, et al.
Published: (2019-04-01)

Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
by: Patrizia Chiusolo, et al.
Published: (2022-08-01)

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission
by: Xi Jia, et al.
Published: (2024-02-01)

Transcriptomic Analysis Identifies RNA Binding Proteins as Putative Regulators of Myelopoiesis and Leukemia
by: Subha Saha, et al.
Published: (2019-08-01)

Minimal Residual Disease as a Predictive Factor for Relapse after Allogeneic Hematopoietic Stem Cell Transplant in Adult Patients with Acute Myeloid Leukemia in First and Second Complete Remission
by: Rada M. Grubovikj, et al.
Published: (2012-06-01)

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia
by: Justin Loke, et al.
Published: (2021-04-01)

Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation
by: Mark-Alexander Schwarzbich, et al.
Published: (2022-02-01)

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia
by: Joan So, et al.
Published: (2022-07-01)

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
by: Monica Bocchia, et al.
Published: (2018-05-01)

Molecular Systems Architecture of Interactome in the Acute Myeloid Leukemia Microenvironment
by: V. A. Shiva Ayyadurai, et al.
Published: (2022-02-01)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
by: Mark P. Chao, et al.
Published: (2020-01-01)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
by: Ing S. Tiong, et al.
Published: (2023-03-01)

GABP is necessary for stem/progenitor cell maintenance and myeloid differentiation in human hematopoiesis and chronic myeloid leukemia
by: Georgi Manukjan, et al.
Published: (2016-05-01)

Molecular Mechanisms in Murine Syngeneic Leukemia Stem Cells
by: Michael Chamo, et al.
Published: (2023-01-01)

Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity
by: Marlon Arnone, et al.
Published: (2020-12-01)

Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects
by: Elena N. Parovichnikova, et al.
Published: (2021-07-01)

Liquid biopsies and minimal residual disease in myeloid malignancies
by: Sabine Allam, et al.
Published: (2023-05-01)